Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML

Inclusion Criteria:

Must be ≥18 and ≤70 years of age.
Must have confirmed diagnosis of AML in first or second complete remission (CR1 or CR2) or have bone marrow blasts ≤10% without circulating blasts.
AML sample from the patient must have evidence of CD33 expression (>0%)
AML must have intermediate or high-risk disease-related genetics and the presence of minimal residual disease (MRD). Subjects in CR2 or with persistent morphologic blasts; may have favorable disease-related genetics.
Candidate for HLA-matched allogeneic HCT using a myeloablative conditioning regimen.
Must have a related or unrelated stem cell donor that is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1.

Must have adequate performance status and organ function as defined below:

Performance Status: Karnofsky score of ≥70.
Cardiac: left ventricular ejection fraction (LVEF) ≥50%
Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO), forced vital capacity (FVC), and forced expiratory volume in one second (FEV1) ≥66%.
Renal: estimated glomerular filtration rate (GFR) >60 mL/min
Hepatic: total bilirubin <1.5 × ULN, or if ≥1.5 × ULN direct bilirubin
Exclusion Criteria:

Prior autologous or allogeneic stem cell transplantation.
Presence of the following disease-related genetics: t(15; 17)(q22; q21), or t(9; 22)(q34; q11), or other evidence of acute promyelocytic leukemia or chronic myeloid leukemia.
Prior treatment with Mylotarg™ (gemtuzumab ozogamicin).
Active central nervous system (CNS) leukemia or history of other active malignancy(ies).
Patients diagnosed with Gilbert's syndrome.
Uncontrolled bacterial, viral, or fungal infections; or known human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection.